Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary
Niagen Bioscience IncQ) reported adjusted earnings of 6 cents per share for the quarter ended March 31, surpassing last year's EPS of -1 cent and analysts' expectations of 2 cents. Revenue increased by 37.6% to $30.48 million, exceeding the forecast of $27.10 million. The company achieved a net income of $5.06 million. Niagen's shares rose 26.5% this quarter and 64.6% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $8.05.
Niagen Bioscience Inc (NAGE.OQ) reported quarterly adjusted earnings of 6 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of four analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 3 cents per share.
Revenue rose 37.6% to $30.48 million from a year ago; analysts expected $27.10 million.
Niagen Bioscience Inc’s reported EPS for the quarter was 6 cents.
The company reported quarterly net income of $5.06 million.
Niagen Bioscience Inc shares had risen by 26.5% this quarter and gained 64.6% so far this year. FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS
The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 4 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is also “buy”
Wall Street’s median 12-month price target for Niagen Bioscience Inc is $8.05 This summary was machine generated from LSEG data May 7 at 09:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2025 0.02 0.06 Beat
Dec. 31 2024 0.02 0.09 Beat
Sep. 30 2024 0.00 0.02 Beat
Jun. 30 2024 -0.02 0.00 Beat
